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Abstract
Background: Hypoxia-induced radioresistance constitutes a major obstacle for a curative treatment of cancer. The
aim of this study was to investigate effects of photon and carbon ion irradiation in combination with inhibitors of
DNA-Damage Response (DDR) on tumor cell radiosensitivity under hypoxic conditions.
Methods: Human non-small cell lung cancer (NSCLC) models, A549 and H1437, were irradiated with dose series of
photon and carbon ions under hypoxia (1% O2) vs. normoxic conditions (21% O2). Clonogenic survival was studied
after dual combinations of radiotherapy with inhibitors of DNA-dependent Protein Kinase (DNAPKi, M3814) and
ATM serine/threonine kinase (ATMi).
Results: The OER at 30% survival for photon irradiation of A549 cells was 1.4. The maximal oxygen effect measured as
survival ratio was 2.34 at 8 Gy photon irradiation of A549 cells. In contrast, no significant oxygen effect was found after
carbon ion irradiation. Accordingly, the relative effect of 6 Gy carbon ions was determined as 3.8 under normoxia and.
4.11 under hypoxia. ATM and DNA-PK inhibitors dose dependently sensitized tumor cells for both radiation qualities.
For 100 nM DNAPKi the survival ratio at 4 Gy more than doubled from 1.59 under normoxia to 3.3 under hypoxia
revealing a strong radiosensitizing effect under hypoxic conditions. In contrast, this ratio only moderately increased
after photon irradiation and ATMi under hypoxia. The most effective treatment was combined carbon ion irradiation
and DNA damage repair inhibition.
Conclusions: Carbon ions efficiently eradicate hypoxic tumor cells. Both, ATMi and DNAPKi elicit radiosensitizing
effects. DNAPKi preferentially sensitizes hypoxic cells to radiotherapy.
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Background
Tumor hypoxia is a critical factor contributing to ac-
quired radioresistance and therapy failure [1, 2]. In line,
tumor hypoxia was shown to correlate with poor
prognosis and inferior therapeutic outcome in non-small
cell lung cancer (NSCLC) [3, 4]. The lack of oxygen
leads to decreased production of reactive oxygen species
and consequently to reduced DNA damage after conven-
tional radiotherapy with high energy photons [5, 6]. In
vitro studies are usually conducted at relatively high oxy-
gen concentrations (20%) compared to the physiological
range of 3–7.4% detected in normal tissues [7]. In tumor
tissues, average oxygen levels are found to be even lower
than 2%, hence referring to a hypoxic microenvironment
[8]. There is a relationship between decreased oxygen
tension and gradual decline of radiation cell killing chan-
ging with different radiation qualities [9]. However,
relevant in vitro data on oxygen enhancement ratio
(OER) measurements are sparse [10] but urgently
needed to adjust treatment planning with more faithful
oxygen concentrations and to evaluate the impact of dif-
ferent radiation qualities and multimodal treatments.
Induction of DNA damage is a hallmark of radiation
induced cell toxicity [11]. The relevant, lethal DNA
damage, complex double-strand breaks (DSB), are
repaired by two major pathways, i.e., homologous
recombination and non-homologous end-joining. For each
of these pathways, members of the phosphotidylinositol-3-
kinase (PIK) family are recruited to DSBs: Ataxia-
telangiectasia mutated (ATM) and DNA-dependent protein
kinase with its catalytic subunit (DNA-PKc). Inhibitors of
these key players in DNA damage response (DDR)
pathways were shown to enhance the efficacy of radiother-
apy [12]. In contrast to sparsely ionizing photon radiation,
carbon ions are densely ionizing along their traversal and
are considered high linear energy transfer (LET) irradiation
[13]. The application of high-LET beams has been shown
to increase tumor cell killing by inducing more complex
DNA damage that results in an increased radiobiological
effectiveness (RBE) [14]. It has been further reported that
cell killing by high-LET radiation might be less dependent
on the tumor oxygen status [9, 15].
In this study, the effect of carbon ions vs. conven-
tional photon irradiation was investigated on two
NSCLC cell lines. We report on the radiosensitizing
effect of two novel DDR inhibitors, DNAPKi and
ATMi, with photon- and carbon ion irradiation under
hypoxic conditions.
Methods
Cell lines
The US National Cancer Institute (NCI) offers a panel of 60
human tumor cell lines (NCI-60 panel, https://dtp.cancer.-
gov/discovery_development/nci-60/) for in vitro evaluations
including anti-cancer compounds [16]. From this panel, the
NSCLC cell lines A549 and NCI-H1437 (H1437) cells were
purchased from the American Type Culture Collection
(ATCC). Cells were grown in RPMI 1640 Medium (Gibco)
supplemented with 10% Fetal Bovine Serum (FBS) at 37 °C
and 5% CO2 atmosphere. Experiments in hypoxic condi-
tions were performed at 1% O2 and 5% CO2.
Experimental design
To assess clonogenic survival under hypoxic conditions,
we devised a system to irradiate cells in 96-well plates
while incubated in a hypoxia chamber (C-chamber;
Biospherix) allowing online monitoring of CO2 and O2
concentrations (ProOx and ProCO2 model; Biospherix)
during the entire experiment (Fig. 1a). 50, 100 or 200
A549 cells/well and 100, 200 or 300 H1437 cells /well
were seeded up to 16 h before irradiation. Cell numbers
increased with escalation of dose and drug concentra-
tion. Inhibitors were added to the cells at 50 nM,
100 nM, 200 nM, 500 nM, or 1000 nM for normoxia
and at 100 nM, 200 nM, or 500 nM for hypoxia and at
100 nM for carbon ion irradiation. Both ATM and
DNA-PK inhibitors were dissolved in DMSO and diluted
in RPMI 1640 medium. Controls also contained <0.1%
DMSO. To determine the effect of drug treatment alone
on clonogenic survival (Plating efficiency, PE), dose
series of both compounds at 0, 50, 100, 200, 500, and
1000 nM were analyzed without irradiation. After expos-
ure to inhibitors, cells were incubated for 4 h in hypoxia
or in normoxia, respectively. For photon radiation, a ver-
tical beam direction was used to irradiate plates at four
different doses. For horizontal carbon ion beams, an ir-
radiation plan was developed to deliver four different
doses in SOBP region of the beam.
Cells were irradiated in the hypoxia chamber with a
dose series of photons (1, 2, 4, or 8 Gy) and carbon
ions (approx. 1, 2, 4, or 6 Gy) and thereafter incu-
bated under normoxic conditions. Inhibitors were left
in the media for 24 h and then replaced with fresh
RPMI 1640 medium and the plates were returned to
the incubator for colony formation. After 4 (A549) or
7 days (H1437) plates were imaged by microscopy at
4× magnification (IncuCyte, Essen Bioscience). The
images were analyzed by the IncuCyte Zoom Software
(Essen Bioscience) and colony counts were confirmed
by manual curation. Counts were normalized to non-
irradiated samples at each corresponding baseline in-
hibitor concentration.
Dose planning and simulations
Photon planning was done with Raystation treatment
planning system (RaySearch Laboratories) based on a
CT scan of the hypoxia chamber containing 96-well
plates filled with water. Irradiation was performed on a
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Siemens Artiste (6 MV). For carbon ion delivery,
Spread-out Bragg peak (SOBP) was physically optimized
with the Treatment Planning for Particles (TRiP98) sys-
tem, using a 30x30x30 cm3 water phantom positioned at
100 cm source-surface distance (SSD) [17]. To reduce
physical uncertainties on cell survival introduced by the
heterogeneous target, a detailed geometry of the utilized
96-well plates was incorporated into a FLUKA Monte
Carlo simulation of the Heidelberg Ion Beam Therapy
(HIT) beam-line [18]. Dose maps were generated, with
dose uniformity found to be within 2% range in the
SOBP region. Carbon dose levels for planned 1, 2, 4 and
6 Gy were corrected accordingly to actual prescribed
0.95, 1.9, 3.8, and 5.64 Gy.
a
b
Fig. 1 Oxygen effect after photon and carbon ion irradiation. a Schematic of the devised hypoxia chamber and 96-well cell culture plates setup
for high-throughput clonogenic survival analysis in vertical photon and horizontal carbon ion beam direction. Hypoxia was continuously monitored by
sensors for O2 and CO2 concentrations. b Clonogenic survival of the NSCLC cell line A549 irradiated under normoxia (black) and hypoxia (1% O2, red)
with photons (solid line) and carbon ions (dashed line). In contrast to carbon irradiation, a significant ratio of survival fractions hypoxia vs. normoxia
was found at doses ≥4 Gy after photon irradiation. Consequently, the RBE of carbon ions was enhanced under hypoxic conditions. Bars represent
mean ± SD of three independent experiments with n:4 technical replicates each. SOBP: Spread-Out Bragg Peak, PMMA: Poly(methyl methacrylate) for
tissue/water-equivalent thickness, arrows: beam direction, *: p < 0.05, **: p < 0.01
Klein et al. Radiation Oncology  (2017) 12:208 Page 3 of 8
Software and calculations
The survival fractions derived from the clonogenic sur-
vival data were fitted according to the linear-quadratic
model for photons. A linear model was applied to car-
bon ion data. The fits as well as OER, RBE, and SER
values (Additional file 1: Table S5 and Table S6) were
calculated using an in-house tool based on Minuit
package available in ROOT [19]. PE values were plotted
with GraphPad Prism 5. To display the oxygen effect,
the relative effect of carbon ions, and the sensitization
effect of inhibitors, measured data points were used to
determine ratios of clonogenic survival at a correspond-
ing dose: Ratios were calculated as survival fractions of
hypoxic cells and normoxic cells; survival fractions of
cells irradiated with photons and cells irradiated with
carbon ions; survival fractions of mock-treated cells and
cells treated with inhibitors at the same dose, respect-
ively. Effects were compared at a preferential dose of
4 Gy being a reasonable dose for patients in fractionated
therapy.
Statistics
Data are presented as means and standard deviations
(SD). Statistical significance was determined using
unpaired t-test (two-tailed). The asterisks represent
significantly different values. Data represent average
values of at least three independent experiments, each
performed with technical quadruplicates (n:4).
Results
Oxygen effect and relative effect for photon vs. carbon
irradiation under hypoxia
Hypoxia increased the survival fraction of A549 cells sig-
nificantly (between 1.36 to 2.34-fold) at photon doses
≥4 Gy under hypoxia vs. normoxia (p < 0.05). In con-
trast, no significant oxygen effect was found after carbon
ion irradiation (Fig. 1b, Table 1). The calculated OER at
30% survival was 1.4 for photons and 1.2 for carbon ions
(Additional file 1: Table S5A). Accordingly, the survival
ratios displaying the relative effect of carbon ion vs.
photon irradiation at 4 Gy increased from 3.8 under
normoxia to 4.11 at 1% O2 concentration (Table 2).
Corresponding RBE values calculated from fits at 30%
survival are 2.7 under normoxia and 3.1 under hypoxia.
The survival data for H1437 cells are presented in the
supplemental material.
Preferential Radiosensitization of hypoxic cells to DNAPKi
Next, we investigated the inherent and radiosensitizing
effect of two novel DNAPK and ATM serine-threonine
kinase inhibitors. The PE was not significantly reduced
after ATMi treatment. The PE was only significantly re-
duced by 15% after 1000 nM of DNAPKi (Fig. 2). This is
in line with the reported high selectivity and on target
potency of these compounds: DNAPKi (M3814) is a
highly potent and selective inhibitor of DNA-PK with
subnanomolar potency on its target [20, 21]. The split to
closely related PIKK proteins has been measured in bio-
chemical assays and is about 150-fold to PI3K delta and
greater than 400-fold to the other family members
(ATM, PI3Kalpha – delta, mTOR). The preclinical ATM
inhibitor tested is a subnanomolar potent inhibitor with
50-fold selectivity over DNA-PK and greater than 1000-
fold selectivity against the other PIKK family members
(ATR, PI3Kalpha – delta, mTOR).
After photon irradiation both compounds exhibited
dose dependent radiosensitizing effects under normoxic
and hypoxic conditions (Fig. 3). For 100 nM ATMi, the
sensitization effect at 4 Gy photons increased from 1.4
under normoxia to 1.6 under hypoxia (Table 3). The
radiosensitizing effect of DNAPKi was markedly
enhanced under hypoxic conditions. For 100 nM
DNAPKi the survival ratio at 4 Gy more than doubled
from 1.5 under normoxia to 3.3 under hypoxia (Fig. 3,
Table 3). The enhanced sensitizing effect of DNAPKi
under hypoxia was found in both cell lines (Additional
file 1: Fig. S3).
Effect of DDR inhibition in combination with carbon ion
irradiation
Next, we aimed to discover the potential of DDR
inhibitors to further improve eradication of radioresis-
tant hypoxic cells. Based on the PE data demonstrating
no relevant cytotoxicity at 100 nM for both inhibitors
(Fig. 2), but strong radiosensitizing effects after photon
irradiation (Fig. 3), this concentration was selected for
combinations with carbon ion irradiation. Both inhibi-
tors exhibit potent radiosensitizing effects in combin-
ation with high-LET carbon irradiation (Fig. 4). The SER
Table 1 Ratio of survival fractions normoxia vs. hypoxia for
A549 cells at indicated doses
Normoxia Hypoxia p-value Ratio
SF4Gy Photons 0.44 ± 0.07 0.59 ± 0.02 0.025 1.36 ± 0.18
SF8Gy Photons 0.11 ± 0.04 0.27 ± 0.03 0.004 2.34 ± 0.56
SF3.8Gy Carbon ions 0.11 ± 0.03 0.14 ± 0.03 0.29 1.25 ± 0.13
SF5.6Gy Carbon ions 0.05 ± 0.01 0.06 ± 0.02 0.35 1.32 ± 0.02
Abbreviations: SF survival fraction at indicated dose
Table 2 Relative effect of photons vs. carbon ions for A549 cells
at the indicated dose
SF4Gy
Photons Carbon ions p-value Ratio
Normoxia 0.44 ± 0.07 0.12 ± 0.03 0.002 3.8 ± 0.20
Hypoxia 0.59 ± 0.02 0.14 ± 0.03 <0.0001 4.11 ± 0.34
Abbreviations: SF4Gy survival fraction at 4 Gy photons and 3.8 Gy carbon ions
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at 30% survival was 1.5 for 100 nM ATMi and carbon ir-
radiation under normoxic conditions (Additional file 1:
Table S5B). This radiosensitizing effect was not further
enhanced by addition of ATMi to carbon ions under
hypoxic condition. In contrast, the SER at 30% survival
increased from 1.7 under normoxia to 1.9 under hypoxia
after combined carbon irradiation and DNAPKi. When
comparing survival ratios after treatment with DNAPKi
and 4 Gy carbon ion irradiation the ratios increased
from 3.4 to 5.1 normoxia vs. hypoxia (Table 4). Overall,
combination of DNAPKi and carbon irradiation most
efficiently eradicated hypoxic NSCLC tumor cells.
Discussion
We report here efficient eradication of hypoxic NSCLC
tumor cells, in particular, after combined DNAPKi and
ionizing radiation. Both, ATMi and DNAPKi demon-
strated a gradual dose dependent radiosensitizing effect
under normoxia and hypoxic conditions. Our data fur-
ther confirmed findings from previous work reporting
a b
Fig. 2 Lack of cytotoxicity of utilized ATMi and DNAPKi alone at pharmacologically relevant doses. PE of A549 cells after treatment with dose series of
ATMi (light grey) or DNAPKi (dark grey), respectively, under normoxia (a) and hypoxia (b). Statistically significant reduction of PE was only found under
normoxia for doses ≥1000 nM. Bars represent mean ± SD of three independent experiments with n:4 technical replicates each
a b
Fig. 3 Dose dependent radiosensitizing effect of ATMi and DNAPKi after photon irradiation. Clonogenic survival of A549 tumor cells irradiated
with photons under normoxia (a) and hypoxia (b) in combination with increasing concentrations of ATMi (upper panel) or DNAPKi (lower panel),
respectively. Both DDR inhibitors exhibited potent dose dependent radiosensitizing effects. Note, the ratio of survival fractions with and without
DNAPKi increased significantly under hypoxic conditions (Table 3). Bars represent mean ± SD of three independent experiments with n:4 technical
replicates each. **: p < 0.01; ***: p < 0.005
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on a minimal dependency of high-LET carbon beams on
cellular oxygen concentration [22, 23]. A combination of
DNAPKi and carbon ions most efficiently eradicated
hypoxic tumor cells (Fig. 4b).
To investigate irradiation effects under hypoxic condi-
tions, establishing an in vitro experimental approach clos-
est to the in vivo situation was a prerequisite. Current
systems for conducting radiation experiments under hyp-
oxic conditions may show some limitations e.g., utilize a
strict anoxic environment that may not reflect the moder-
ate hypoxic niche of the radioresistant tumor cell popula-
tions [24, 25]. We devised a system that allows to work
with standard cell culture plates and conveniently transfer
them between normoxia and different online monitored
hypoxic conditions such as the 1% O2 utilized in this
study. Moreover, the high-throughput performance in 96-
well format with cell lines that form circumscribed
colonies outperforms currently existing petri dish-sized
hypoxia systems [26]. With this option, we were able to
combine potential radiosensitizers with irradiation in an
identical setting under normoxia and hypoxia.
ATM and DNA-PKc are two central constituents of
DDR and their inhibition was shown to radiosensitize
NSCLC cell lines [27, 28] as well as other tumor entities
[29, 30] to photon irradiation under normoxia. However,
only little is known about the effect of DNA-PKc
inhibition on the radiosensitivity of hypoxic cells. Lind-
quist and colleagues described radiosensitivity effects
with photon irradiation of DNA-PK deficient mouse
embryonic fibroblast cells (SCID/st) under normoxic
and hypoxic conditions compared to isogenic DNA-PK
wildtype cells (CB.17) and that DNA-PK inhibition in
combination with photon irradiation decreases the
clonogenic survival of both oxic and hypoxic cells [31].
Table 3 Effect of ATMi and DNAPKi for photon irradiation of A549 cells at indicated doses
Normoxia Hypoxia
Photons 0 nM 100 nM ATMi p-value Ratio 0 nM 100 nM ATMi p- value Ratio
SF4Gy 0.43 ± 0.07 0.29 ± 0.10 0.12 1.48 ± 0.25 0.59 ± 0.02 0.37 ± 0.07 0.007 1.57 ± 0.23
SF8Gy 0.11 ± 0.04 0.05 ± 0.01 0.06 2.11 ± 0.31 0.27 ± 0.03 0.12 ± 0.02 0.002 2.30 ± 0.26
100 nM DNAPKi 100 nM DNAPKi
SF4Gy 0.29 ± 0.07 0.12 1.51 ± 0.09 0.18 ± 0.01 <0.0001 3.34 ± 0.04
SF8Gy 0.07 ± 0.03 0.072 1.59 ± 0.14 0.07 ± 0.03 0.0002 9.03 ± 3.83
Abbreviations: SF, survival fraction at indicated dose
a b
Fig. 4 DNAPKi further augments efficient eradication of hypoxic tumor cells by carbon ion. Clonogenic survival data for A549 cells irradiated with carbon
ions under normoxia (a) and hypoxia (b) in combination with 100 nM ATMi (upper panel) or DNAPKi (lower panel), respectively. Both inhibitors
radiosensitized carbon ions under normoxia. In line with photon irradiation, with DNAPKi the ratio of survival fractions was further increased after carbon
irradiation under hypoxic conditions. Bars represent mean ± SD of three independent experiments with n:4 technical replicates each. *: p< 0.05, **: p< 0.01
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They suggested that impairment of DNA-PK radiosensi-
tizes independently of cellular oxygen status. In contrast,
we found a marked enhancement of DNAPKi radiosensi-
tizing effects under hypoxia, in both cell lines, but not for
ATM inhibition. One plausible explanation for this
phenomenon is that moderate hypoxia may alter DNA re-
pair signaling e.g., by post-translational modifications in a
HIF-dependent manner [32]. Our data suggest that the
therapeutic window for DNAPKi might be broader than
originally anticipated by efficient eradication of the most
radioresistant cells residing in the hypoxic tumor niche.
This hypothesis, once successfully confirmed by in vivo
experiments, could form the basis for rationally designed
clinical trials investigating the impact of DNAPKi in
otherwise radioresistant hypoxic tumors.
In addition to pharmacological radiosensitization of
hypoxic cells, we provide here novel rationale to
combine DDR inhibitors with high-LET carbon ion ir-
radiation. The high RBE of carbon ions is attributed to
their ability to form more complex unrepairable DSB
correlating with large nuclear repair foci and increased
number of residual DNA damage [14, 33]. Our results
with NSCLC cell lines confirm data for CHO-K1 cells
[26] showing that the low dependency of high-LET ir-
radiation on cellular oxygen would further increase the
RBE under hypoxic conditions. Additionally, these find-
ings justify the usage of carbon ions to treat patients
with hypoxia-associated radioresistant tumors.
We further evaluated the significance of inhibiting DDR
with carbon ions. Interestingly, the sensitizing effect of
DNAPKi was more pronounced than the effect of ATM
inhibition. Moreover, the DNAPKi sensitizing effect was
substantially enhanced (between ~50–60%) in survival
ratios after carbon irradiation under hypoxic compared to
normoxic conditions. On the contrary, the ATMi sensitiz-
ing effect remained in the same range under hypoxic vs.
normoxic conditions after carbon ion irradiation. It is
conceivable that the formation of lethal complex DNA
damages is enhanced with higher photon doses, higher
LET and inhibition of DNA-PKc. However, further mech-
anistic studies are needed to dissect the molecular mecha-
nisms underlying the superior radiosensitizing principle
behind DNAPKi treatment under hypoxic conditions.
Conclusion
Dual therapy with DNAPKi and carbon ion irradiation
demonstrated the highest efficacy in eradicating other-
wise radioresistant hypoxic tumors. Our data suggest po-
tent reversal of the radioresistant phenotype of hypoxic
tumors by DNAPKi that warrants further preclinical and
clinical evaluation.
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Additional file 1: S1-S4 Clonogenic survival of H1437 cells; In parallel to
A549, another NSCLC cell line, H1437, was used in the same setup to
compare the oxygen effect as well as sensitizing effects of inhibitors with
photon vs. carbon ion irradiations. S5 Table listing OER, RBE, and SER for
A549 and H1437 cells. OER, RBE, and SER were calculated from linear
quadratic fits at 30% survival. (PDF 524 kb)
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